Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Systemic Lupus Erythematosus
NCT00036491Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2001
- Primary completion
- Jan 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in systemic lupus erythematosus (SLE), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Serum Autoantibodies at Week 56 and Systemic Lupus Erythematosus Disease Activity Index at Week 55. Started Jan 2001; status: completed.
02
Drugs
rituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00036491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036491.